| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 77 | 2023 | 133 | 18.840 |
Why?
|
| Anticoagulants | 115 | 2023 | 294 | 13.480 |
Why?
|
| Pulmonary Embolism | 61 | 2022 | 126 | 8.260 |
Why?
|
| Venous Thrombosis | 47 | 2021 | 98 | 7.880 |
Why?
|
| Factor Xa Inhibitors | 37 | 2021 | 54 | 7.570 |
Why?
|
| Hemorrhage | 75 | 2023 | 265 | 6.740 |
Why?
|
| Thiazoles | 19 | 2021 | 51 | 5.600 |
Why?
|
| Pyridines | 20 | 2021 | 107 | 5.030 |
Why?
|
| Rivaroxaban | 18 | 2023 | 29 | 4.820 |
Why?
|
| Warfarin | 40 | 2023 | 94 | 3.920 |
Why?
|
| Enoxaparin | 27 | 2022 | 37 | 3.210 |
Why?
|
| Neoplasms | 19 | 2022 | 809 | 3.080 |
Why?
|
| Fibrinolytic Agents | 15 | 2017 | 70 | 2.370 |
Why?
|
| Dalteparin | 6 | 2020 | 7 | 2.310 |
Why?
|
| Humans | 218 | 2023 | 28097 | 2.230 |
Why?
|
| Arthroplasty, Replacement, Knee | 14 | 2021 | 38 | 2.200 |
Why?
|
| Thrombosis | 11 | 2020 | 149 | 2.190 |
Why?
|
| Risk Factors | 51 | 2023 | 2081 | 2.180 |
Why?
|
| Pyridones | 14 | 2020 | 35 | 2.170 |
Why?
|
| Heparin, Low-Molecular-Weight | 24 | 2020 | 35 | 2.130 |
Why?
|
| Pyrazoles | 14 | 2020 | 66 | 2.120 |
Why?
|
| Double-Blind Method | 50 | 2020 | 417 | 2.060 |
Why?
|
| Aged | 90 | 2021 | 5400 | 2.060 |
Why?
|
| Vitamin K | 18 | 2018 | 39 | 1.960 |
Why?
|
| Thrombophlebitis | 35 | 1999 | 51 | 1.860 |
Why?
|
| Middle Aged | 95 | 2021 | 7138 | 1.830 |
Why?
|
| Thromboembolism | 23 | 2014 | 57 | 1.640 |
Why?
|
| Heparin | 37 | 2016 | 111 | 1.620 |
Why?
|
| Male | 113 | 2021 | 13491 | 1.610 |
Why?
|
| Treatment Outcome | 48 | 2021 | 2379 | 1.590 |
Why?
|
| Aftercare | 8 | 2022 | 33 | 1.540 |
Why?
|
| Patient Discharge | 9 | 2022 | 104 | 1.540 |
Why?
|
| Female | 116 | 2022 | 15156 | 1.540 |
Why?
|
| Blood Coagulation | 10 | 2019 | 118 | 1.500 |
Why?
|
| Hospitalization | 8 | 2022 | 198 | 1.420 |
Why?
|
| Recurrence | 35 | 2023 | 322 | 1.400 |
Why?
|
| Arthroplasty, Replacement, Hip | 9 | 2013 | 29 | 1.390 |
Why?
|
| Postoperative Complications | 18 | 2021 | 611 | 1.360 |
Why?
|
| Administration, Oral | 28 | 2021 | 189 | 1.340 |
Why?
|
| Time Factors | 32 | 2021 | 1592 | 1.240 |
Why?
|
| Oligosaccharides | 5 | 2014 | 33 | 1.170 |
Why?
|
| Incidence | 15 | 2022 | 562 | 1.100 |
Why?
|
| Drug Administration Schedule | 25 | 2019 | 224 | 1.100 |
Why?
|
| Research Design | 9 | 2016 | 184 | 1.080 |
Why?
|
| Randomized Controlled Trials as Topic | 20 | 2020 | 385 | 1.050 |
Why?
|
| Cost of Illness | 3 | 2015 | 54 | 1.040 |
Why?
|
| Adult | 57 | 2022 | 7740 | 1.030 |
Why?
|
| Risk Assessment | 19 | 2022 | 612 | 1.020 |
Why?
|
| Prospective Studies | 33 | 2022 | 1248 | 1.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 144 | 0.960 |
Why?
|
| Follow-Up Studies | 26 | 2021 | 1013 | 0.940 |
Why?
|
| United States | 22 | 2022 | 2146 | 0.810 |
Why?
|
| Secondary Prevention | 8 | 2016 | 46 | 0.810 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 8 | 2003 | 94 | 0.760 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 4 | 2008 | 10 | 0.760 |
Why?
|
| Acute Disease | 17 | 2021 | 155 | 0.740 |
Why?
|
| Chemoprevention | 2 | 2020 | 32 | 0.710 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 17 | 0.710 |
Why?
|
| Injections, Subcutaneous | 22 | 2021 | 60 | 0.690 |
Why?
|
| Polysaccharides | 7 | 2009 | 62 | 0.680 |
Why?
|
| Critical Illness | 1 | 2021 | 66 | 0.680 |
Why?
|
| Thrombophilia | 1 | 2020 | 10 | 0.680 |
Why?
|
| Aged, 80 and over | 27 | 2021 | 2021 | 0.660 |
Why?
|
| Inpatients | 1 | 2020 | 56 | 0.660 |
Why?
|
| Awareness | 2 | 2016 | 16 | 0.630 |
Why?
|
| Models, Economic | 3 | 2015 | 8 | 0.610 |
Why?
|
| Health Care Costs | 4 | 2015 | 50 | 0.600 |
Why?
|
| Global Health | 2 | 2015 | 51 | 0.570 |
Why?
|
| Population Surveillance | 2 | 2015 | 86 | 0.550 |
Why?
|
| Biotin | 2 | 2014 | 25 | 0.540 |
Why?
|
| Health Facilities | 1 | 2017 | 11 | 0.540 |
Why?
|
| Primary Prevention | 1 | 2017 | 25 | 0.530 |
Why?
|
| Health Services Research | 1 | 2017 | 43 | 0.530 |
Why?
|
| Global Burden of Disease | 1 | 2016 | 7 | 0.510 |
Why?
|
| Decision Support Techniques | 6 | 2018 | 50 | 0.510 |
Why?
|
| Survival Rate | 7 | 2021 | 430 | 0.500 |
Why?
|
| Prognosis | 11 | 2021 | 803 | 0.480 |
Why?
|
| Stroke | 3 | 2018 | 252 | 0.470 |
Why?
|
| Age Factors | 8 | 2021 | 734 | 0.470 |
Why?
|
| Atrial Fibrillation | 6 | 2018 | 402 | 0.460 |
Why?
|
| Cost-Benefit Analysis | 12 | 2013 | 112 | 0.450 |
Why?
|
| Hemostasis | 1 | 2014 | 48 | 0.450 |
Why?
|
| Clinical Trials as Topic | 14 | 2020 | 214 | 0.440 |
Why?
|
| Predictive Value of Tests | 11 | 2018 | 474 | 0.420 |
Why?
|
| Lung | 11 | 2008 | 379 | 0.410 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2021 | 607 | 0.400 |
Why?
|
| Dabigatran | 4 | 2023 | 20 | 0.400 |
Why?
|
| Ultrasonography | 11 | 2021 | 241 | 0.390 |
Why?
|
| Blood Coagulation Tests | 2 | 2013 | 27 | 0.390 |
Why?
|
| Plethysmography, Impedance | 15 | 1999 | 17 | 0.380 |
Why?
|
| Thrombin | 3 | 2019 | 69 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 194 | 0.380 |
Why?
|
| Evidence-Based Medicine | 6 | 2013 | 145 | 0.360 |
Why?
|
| Registries | 6 | 2012 | 387 | 0.340 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 6 | 0.340 |
Why?
|
| Hypertension, Pulmonary | 4 | 2012 | 34 | 0.330 |
Why?
|
| Adolescent | 18 | 2021 | 3122 | 0.320 |
Why?
|
| Risk | 10 | 2018 | 137 | 0.310 |
Why?
|
| Clinical Decision-Making | 3 | 2018 | 63 | 0.310 |
Why?
|
| Patient Selection | 2 | 2020 | 148 | 0.310 |
Why?
|
| Factor XI | 2 | 2021 | 3 | 0.300 |
Why?
|
| Phlebography | 11 | 2010 | 20 | 0.300 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 452 | 0.300 |
Why?
|
| Comorbidity | 2 | 2020 | 258 | 0.290 |
Why?
|
| Ventilation-Perfusion Ratio | 9 | 2004 | 12 | 0.290 |
Why?
|
| Sensitivity and Specificity | 10 | 2007 | 521 | 0.280 |
Why?
|
| Catheterization, Central Venous | 1 | 2007 | 38 | 0.280 |
Why?
|
| Tomography, Spiral Computed | 2 | 2004 | 8 | 0.270 |
Why?
|
| Public Health | 2 | 2016 | 93 | 0.270 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2016 | 5 | 0.260 |
Why?
|
| Thiophenes | 3 | 2012 | 14 | 0.260 |
Why?
|
| Schools, Public Health | 1 | 2006 | 3 | 0.260 |
Why?
|
| Morpholines | 3 | 2012 | 28 | 0.260 |
Why?
|
| Orthopedic Procedures | 2 | 2004 | 27 | 0.250 |
Why?
|
| Thrombolytic Therapy | 3 | 1994 | 39 | 0.250 |
Why?
|
| Creatinine | 3 | 2022 | 59 | 0.250 |
Why?
|
| Coronary Disease | 4 | 1995 | 119 | 0.240 |
Why?
|
| Oklahoma | 3 | 2021 | 1007 | 0.240 |
Why?
|
| Biomedical Research | 2 | 2016 | 97 | 0.240 |
Why?
|
| Hematologic Tests | 1 | 2004 | 7 | 0.230 |
Why?
|
| Age Distribution | 3 | 2021 | 73 | 0.230 |
Why?
|
| Factor Xa | 3 | 2018 | 14 | 0.230 |
Why?
|
| Intention to Treat Analysis | 4 | 2017 | 13 | 0.220 |
Why?
|
| Wounds and Injuries | 1 | 2006 | 183 | 0.210 |
Why?
|
| Heart Valves | 1 | 2023 | 10 | 0.210 |
Why?
|
| Drug Therapy, Combination | 8 | 2013 | 208 | 0.210 |
Why?
|
| Partial Thromboplastin Time | 10 | 2021 | 18 | 0.200 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 39 | 0.200 |
Why?
|
| Young Adult | 7 | 2021 | 2733 | 0.200 |
Why?
|
| Logistic Models | 7 | 2017 | 407 | 0.200 |
Why?
|
| Thrombocytopenia | 3 | 1999 | 113 | 0.200 |
Why?
|
| Infusions, Intravenous | 11 | 2021 | 102 | 0.200 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2003 | 81 | 0.190 |
Why?
|
| Factor XIa | 1 | 2021 | 2 | 0.190 |
Why?
|
| Arm | 1 | 2002 | 37 | 0.190 |
Why?
|
| Triazoles | 1 | 2021 | 16 | 0.190 |
Why?
|
| Immobilization | 2 | 2020 | 15 | 0.190 |
Why?
|
| Odds Ratio | 6 | 2018 | 236 | 0.190 |
Why?
|
| Retrospective Studies | 8 | 2021 | 2546 | 0.180 |
Why?
|
| Single-Blind Method | 2 | 2020 | 44 | 0.180 |
Why?
|
| Canada | 8 | 2010 | 60 | 0.180 |
Why?
|
| Bronchiectasis | 1 | 2021 | 3 | 0.180 |
Why?
|
| Patient Admission | 2 | 2020 | 29 | 0.180 |
Why?
|
| Heart Diseases | 2 | 2018 | 70 | 0.180 |
Why?
|
| United Kingdom | 1 | 2021 | 76 | 0.180 |
Why?
|
| Intracranial Hemorrhages | 2 | 2017 | 30 | 0.180 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2021 | 40 | 0.180 |
Why?
|
| Pyrimidines | 1 | 2021 | 125 | 0.170 |
Why?
|
| Critical Pathways | 1 | 2020 | 16 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 330 | 0.170 |
Why?
|
| Preoperative Care | 2 | 2020 | 81 | 0.170 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2020 | 24 | 0.170 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2010 | 9 | 0.170 |
Why?
|
| Europe | 5 | 2016 | 98 | 0.170 |
Why?
|
| Drug Monitoring | 3 | 2013 | 36 | 0.170 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2003 | 216 | 0.170 |
Why?
|
| Equivalence Trials as Topic | 2 | 2016 | 2 | 0.160 |
Why?
|
| Radionuclide Imaging | 12 | 2004 | 56 | 0.160 |
Why?
|
| Factor VIIa | 2 | 2001 | 29 | 0.160 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2019 | 191 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2020 | 61 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2003 | 819 | 0.160 |
Why?
|
| Kidney Diseases | 1 | 2020 | 61 | 0.160 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1999 | 17 | 0.160 |
Why?
|
| Obesity | 2 | 2020 | 669 | 0.160 |
Why?
|
| Cost Savings | 2 | 2015 | 19 | 0.160 |
Why?
|
| Elective Surgical Procedures | 4 | 2010 | 70 | 0.160 |
Why?
|
| Aspirin | 4 | 1995 | 124 | 0.150 |
Why?
|
| Hirudin Therapy | 1 | 1998 | 1 | 0.150 |
Why?
|
| Diagnosis, Differential | 11 | 1998 | 371 | 0.150 |
Why?
|
| Patient Satisfaction | 2 | 2009 | 96 | 0.150 |
Why?
|
| Myocardial Infarction | 4 | 2016 | 346 | 0.150 |
Why?
|
| Clinical Protocols | 4 | 2014 | 46 | 0.150 |
Why?
|
| International Normalized Ratio | 5 | 2017 | 27 | 0.150 |
Why?
|
| Child | 8 | 2012 | 2242 | 0.140 |
Why?
|
| Gangrene | 1 | 1997 | 4 | 0.140 |
Why?
|
| Polypharmacy | 1 | 2017 | 11 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 2 | 1995 | 36 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 297 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2004 | 887 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 54 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 1998 | 172 | 0.130 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 31 | 0.130 |
Why?
|
| Community Participation | 1 | 2017 | 26 | 0.130 |
Why?
|
| Laboratories | 1 | 1996 | 18 | 0.130 |
Why?
|
| Antithrombins | 1 | 2016 | 28 | 0.130 |
Why?
|
| Specimen Handling | 1 | 1996 | 33 | 0.130 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2016 | 8 | 0.130 |
Why?
|
| Research Report | 1 | 2016 | 23 | 0.130 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 12 | 0.130 |
Why?
|
| Quinine | 1 | 2016 | 23 | 0.130 |
Why?
|
| Pulmonary Artery | 5 | 2008 | 69 | 0.120 |
Why?
|
| Sample Size | 1 | 2015 | 17 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1999 | 409 | 0.120 |
Why?
|
| Public Opinion | 1 | 2015 | 8 | 0.120 |
Why?
|
| Ultrasonography, Doppler | 1 | 1995 | 22 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 250 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 4 | 2007 | 243 | 0.120 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2014 | 22 | 0.120 |
Why?
|
| Oligonucleotides | 1 | 2014 | 27 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 1994 | 7 | 0.110 |
Why?
|
| Leg | 5 | 2003 | 134 | 0.110 |
Why?
|
| Embolism | 1 | 1994 | 14 | 0.110 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 2 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2015 | 230 | 0.110 |
Why?
|
| Pregnancy | 6 | 1998 | 1191 | 0.110 |
Why?
|
| Social Class | 1 | 2014 | 81 | 0.110 |
Why?
|
| Chi-Square Distribution | 4 | 2017 | 145 | 0.110 |
Why?
|
| Hip Prosthesis | 4 | 1997 | 11 | 0.110 |
Why?
|
| Electrocardiography | 2 | 2014 | 394 | 0.110 |
Why?
|
| Vascular Resistance | 2 | 2012 | 50 | 0.100 |
Why?
|
| Aging | 2 | 1998 | 968 | 0.100 |
Why?
|
| Factor X | 1 | 2011 | 11 | 0.090 |
Why?
|
| Ambulatory Care | 4 | 2017 | 60 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 31 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2012 | 35 | 0.090 |
Why?
|
| Biomarkers | 3 | 2018 | 765 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2015 | 971 | 0.090 |
Why?
|
| Sulfones | 1 | 2010 | 7 | 0.090 |
Why?
|
| Knee Prosthesis | 3 | 1997 | 6 | 0.090 |
Why?
|
| Pyrimidinones | 1 | 2010 | 16 | 0.090 |
Why?
|
| Morbidity | 1 | 2010 | 58 | 0.080 |
Why?
|
| Postthrombotic Syndrome | 1 | 2009 | 2 | 0.080 |
Why?
|
| Outpatients | 2 | 2007 | 44 | 0.080 |
Why?
|
| Child, Preschool | 4 | 2012 | 1146 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 56 | 0.080 |
Why?
|
| Home Care Services | 1 | 2009 | 37 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2021 | 45 | 0.080 |
Why?
|
| Decision Making | 2 | 2003 | 175 | 0.080 |
Why?
|
| Psychometrics | 1 | 2009 | 121 | 0.070 |
Why?
|
| Abdomen | 3 | 1998 | 41 | 0.070 |
Why?
|
| Pregnancy Complications, Hematologic | 3 | 1998 | 38 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2008 | 32 | 0.070 |
Why?
|
| Hip | 3 | 1989 | 12 | 0.070 |
Why?
|
| Long-Term Care | 2 | 2004 | 32 | 0.070 |
Why?
|
| Body Weight | 3 | 2013 | 250 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2000 | 163 | 0.070 |
Why?
|
| Streptokinase | 1 | 1987 | 5 | 0.070 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1987 | 11 | 0.070 |
Why?
|
| Blood Transfusion | 2 | 2018 | 77 | 0.070 |
Why?
|
| Prothrombin Time | 5 | 1997 | 21 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2007 | 81 | 0.070 |
Why?
|
| Combined Modality Therapy | 4 | 1999 | 300 | 0.060 |
Why?
|
| Accreditation | 1 | 2006 | 35 | 0.060 |
Why?
|
| Cardiac Catheterization | 3 | 2012 | 113 | 0.060 |
Why?
|
| Knee | 1 | 1986 | 25 | 0.060 |
Why?
|
| Autoimmune Diseases | 2 | 1998 | 164 | 0.060 |
Why?
|
| Joints | 1 | 1985 | 12 | 0.060 |
Why?
|
| Research | 1 | 2006 | 92 | 0.060 |
Why?
|
| Splenectomy | 2 | 2003 | 44 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 62 | 0.060 |
Why?
|
| Bone and Bones | 1 | 1985 | 75 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2010 | 78 | 0.060 |
Why?
|
| Organothiophosphorus Compounds | 1 | 2004 | 3 | 0.060 |
Why?
|
| Chemical Warfare Agents | 1 | 2004 | 4 | 0.050 |
Why?
|
| Chemical Warfare | 1 | 2004 | 3 | 0.050 |
Why?
|
| Economics, Pharmaceutical | 1 | 2003 | 6 | 0.050 |
Why?
|
| Hip Fractures | 1 | 2004 | 10 | 0.050 |
Why?
|
| Isoantibodies | 1 | 2003 | 15 | 0.050 |
Why?
|
| Drug Costs | 1 | 2003 | 17 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2003 | 126 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2003 | 103 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2003 | 104 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2002 | 7 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2002 | 5 | 0.050 |
Why?
|
| Heart Valve Prosthesis | 5 | 2001 | 62 | 0.050 |
Why?
|
| Helminth Proteins | 1 | 2001 | 19 | 0.050 |
Why?
|
| Cause of Death | 4 | 2007 | 73 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2010 | 288 | 0.040 |
Why?
|
| Contraindications | 1 | 2000 | 13 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2009 | 226 | 0.040 |
Why?
|
| Plethysmography | 1 | 2000 | 27 | 0.040 |
Why?
|
| Popliteal Vein | 1 | 2000 | 3 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2000 | 474 | 0.040 |
Why?
|
| Femoral Vein | 1 | 2000 | 13 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 19 | 0.040 |
Why?
|
| Thrombin Time | 1 | 2019 | 2 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2000 | 91 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 43 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 722 | 0.040 |
Why?
|
| Radiography | 3 | 1996 | 202 | 0.040 |
Why?
|
| Angiography | 2 | 1999 | 35 | 0.040 |
Why?
|
| Benzamides | 1 | 2018 | 34 | 0.040 |
Why?
|
| Thoracic Surgical Procedures | 1 | 1998 | 5 | 0.040 |
Why?
|
| Injections, Intravenous | 4 | 2008 | 65 | 0.040 |
Why?
|
| Arginine | 1 | 2018 | 42 | 0.040 |
Why?
|
| Hirudins | 1 | 1998 | 17 | 0.040 |
Why?
|
| Piperazines | 1 | 2018 | 47 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 47 | 0.040 |
Why?
|
| Rabbits | 1 | 1998 | 277 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 40 | 0.040 |
Why?
|
| Factor V | 1 | 1997 | 14 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 413 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 1998 | 885 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 126 | 0.030 |
Why?
|
| Random Allocation | 6 | 1986 | 151 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 1996 | 24 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 1998 | 111 | 0.030 |
Why?
|
| Pilot Projects | 2 | 1995 | 433 | 0.030 |
Why?
|
| Government Agencies | 1 | 2016 | 5 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2016 | 29 | 0.030 |
Why?
|
| Chills | 1 | 2016 | 3 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2016 | 7 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 13 | 0.030 |
Why?
|
| Rhabdomyolysis | 1 | 2016 | 6 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 14 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2016 | 11 | 0.030 |
Why?
|
| Beverages | 1 | 2016 | 24 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 31 | 0.030 |
Why?
|
| Blindness | 1 | 2016 | 34 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 23 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 25 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2016 | 34 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 473 | 0.030 |
Why?
|
| Cost Control | 1 | 1995 | 9 | 0.030 |
Why?
|
| Hospitals, University | 1 | 1995 | 26 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 74 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1995 | 56 | 0.030 |
Why?
|
| Probability | 2 | 1995 | 78 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2010 | 68 | 0.030 |
Why?
|
| Heart Aneurysm | 1 | 1994 | 10 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 91 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1994 | 19 | 0.030 |
Why?
|
| Heart Neoplasms | 1 | 1994 | 17 | 0.030 |
Why?
|
| Length of Stay | 1 | 2014 | 229 | 0.030 |
Why?
|
| Infant | 2 | 2012 | 1004 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1994 | 271 | 0.030 |
Why?
|
| Health Promotion | 1 | 2015 | 176 | 0.030 |
Why?
|
| Mutation | 1 | 1997 | 847 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 21 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 961 | 0.030 |
Why?
|
| Drug Evaluation | 2 | 1992 | 11 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 302 | 0.020 |
Why?
|
| Algorithms | 1 | 1995 | 430 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 70 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 466 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 399 | 0.020 |
Why?
|
| Acenocoumarol | 1 | 2010 | 1 | 0.020 |
Why?
|
| Cardiovascular Diseases | 2 | 1992 | 366 | 0.020 |
Why?
|
| Rho(D) Immune Globulin | 2 | 2003 | 12 | 0.020 |
Why?
|
| Gravity Suits | 1 | 1990 | 1 | 0.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1990 | 15 | 0.020 |
Why?
|
| Glucocorticoids | 2 | 2003 | 115 | 0.020 |
Why?
|
| Netherlands | 1 | 2009 | 6 | 0.020 |
Why?
|
| France | 1 | 2009 | 15 | 0.020 |
Why?
|
| Dextrans | 2 | 1986 | 23 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2009 | 68 | 0.020 |
Why?
|
| Cardiography, Impedance | 1 | 1989 | 7 | 0.020 |
Why?
|
| Software | 1 | 1990 | 125 | 0.020 |
Why?
|
| Pressure | 2 | 1986 | 90 | 0.020 |
Why?
|
| Antithrombin III | 1 | 2008 | 6 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 497 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 1989 | 50 | 0.020 |
Why?
|
| Pleurisy | 1 | 1988 | 2 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1989 | 208 | 0.020 |
Why?
|
| North America | 1 | 2008 | 40 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 202 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 68 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 67 | 0.020 |
Why?
|
| Respiration | 2 | 1986 | 45 | 0.020 |
Why?
|
| Methods | 1 | 1986 | 27 | 0.020 |
Why?
|
| Self Administration | 1 | 2007 | 23 | 0.020 |
Why?
|
| Blood Circulation | 1 | 1986 | 13 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 414 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1986 | 12 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 1986 | 31 | 0.020 |
Why?
|
| Technetium | 1 | 1986 | 43 | 0.020 |
Why?
|
| Pulmonary Medicine | 1 | 2006 | 5 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1985 | 24 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2006 | 32 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1985 | 79 | 0.020 |
Why?
|
| Animals | 1 | 1998 | 10423 | 0.010 |
Why?
|
| Information Systems | 1 | 2004 | 7 | 0.010 |
Why?
|
| Disaster Planning | 1 | 2004 | 24 | 0.010 |
Why?
|
| Remission Induction | 1 | 2003 | 53 | 0.010 |
Why?
|
| Prednisone | 1 | 2003 | 54 | 0.010 |
Why?
|
| Focus Groups | 1 | 2004 | 95 | 0.010 |
Why?
|
| Disease Management | 1 | 2003 | 88 | 0.010 |
Why?
|
| Kidney | 1 | 2004 | 286 | 0.010 |
Why?
|
| Communication | 1 | 2004 | 178 | 0.010 |
Why?
|
| Thromboplastin | 1 | 2001 | 28 | 0.010 |
Why?
|
| Ischemic Attack, Transient | 1 | 2001 | 25 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2001 | 73 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2000 | 31 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 48 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 2000 | 29 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 1999 | 9 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2000 | 76 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1999 | 67 | 0.010 |
Why?
|
| Hospitals, Community | 1 | 1998 | 8 | 0.010 |
Why?
|
| Pediatrics | 1 | 2000 | 92 | 0.010 |
Why?
|
| Drug Utilization | 1 | 1998 | 28 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2000 | 143 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2000 | 94 | 0.010 |
Why?
|
| Medical Records | 1 | 1998 | 51 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1998 | 50 | 0.010 |
Why?
|
| Medicare | 1 | 1998 | 124 | 0.010 |
Why?
|
| Bias | 1 | 1997 | 42 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1996 | 4 | 0.010 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 1996 | 4 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1996 | 16 | 0.010 |
Why?
|
| Emergencies | 1 | 1996 | 28 | 0.010 |
Why?
|
| Platelet Count | 1 | 1996 | 111 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 2 | 1986 | 46 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1998 | 769 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1996 | 148 | 0.010 |
Why?
|
| Hematuria | 1 | 1994 | 10 | 0.010 |
Why?
|
| Physician's Role | 1 | 1994 | 29 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1992 | 119 | 0.010 |
Why?
|
| Thigh | 1 | 1990 | 39 | 0.010 |
Why?
|
| Forecasting | 1 | 1989 | 76 | 0.000 |
Why?
|
| Models, Biological | 1 | 1990 | 466 | 0.000 |
Why?
|
| Urogenital System | 1 | 1986 | 3 | 0.000 |
Why?
|
| Hip Joint | 1 | 1986 | 19 | 0.000 |
Why?
|
| Gases | 1 | 1986 | 23 | 0.000 |
Why?
|
| Thoracic Surgery | 1 | 1986 | 14 | 0.000 |
Why?
|
| Knee Joint | 1 | 1986 | 43 | 0.000 |
Why?
|
| Aerosols | 1 | 1986 | 43 | 0.000 |
Why?
|
| Bayes Theorem | 1 | 1985 | 100 | 0.000 |
Why?
|
| Ontario | 1 | 1984 | 10 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1984 | 36 | 0.000 |
Why?
|
| Brain Ischemia | 1 | 1985 | 85 | 0.000 |
Why?
|
| Fibrinogen | 1 | 1984 | 50 | 0.000 |
Why?
|
| Neurosurgical Procedures | 1 | 1986 | 220 | 0.000 |
Why?
|
| Indicators and Reagents | 1 | 1982 | 26 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1982 | 37 | 0.000 |
Why?
|